A reported offer for the established MC4R franchise and fresh funding for Lilly-backed Superluminal point to growing interest in the brain’s hunger pathway. Palatin is engineering several ways to compete in its next generation.
The FDA approved Bayer's asundexian, the first factor XIa inhibitor ever, cutting ischemic stroke risk by 26% on top of antiplatelet therapy with similar overall major bleeding. The class that failed in atrial fibrillation now enters the market as a stroke-recurrence drug.
The first trial of a drug built to lower inherited Lp(a) cut the particle by 78 percent and left event rates unchanged. At least four trials are still running, and none of them repeats the experiment that just failed.